

# Supporting Information

## Marine-Derived Piericidin Diglycoside S18 Alleviates Inflammatory Responses in the Aortic Valve *via* Interaction with Interleukin 37

Shunyi Li <sup>1, #</sup>, Jianglian She <sup>2, 3, #</sup>, Jingxin Zeng <sup>1, 4</sup>, Kaiji Xie <sup>1, 4</sup>, Zichao Luo <sup>1, 4</sup>, Shuwen Su <sup>1, 4</sup>, Jun Chen <sup>1, 4</sup>, Gaopeng Xian <sup>1, 4, 5</sup>, Zhendong Cheng <sup>1, 4</sup>, Jing Zhao <sup>6</sup>, Shaoping Li <sup>6</sup>, Xingbo Xu <sup>7</sup>, Dingli Xu <sup>1, 4, \*</sup>, Lan Tang <sup>3, \*</sup>, Xuefeng Zhou <sup>2, \*</sup>, Qingchun Zeng <sup>1, 4, 5, \*</sup>

<sup>1</sup> State Key Laboratory of Organ Failure Research, Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China

<sup>2</sup> CAS Key Laboratory of Tropical Marine Bio-resources and Ecology, Guangdong Key Laboratory of Marine Materia Medica, South China Sea Institute of Oceanology, Chinese Academy of Sciences, Guangzhou, 510301, China

<sup>3</sup> NMPA Key Laboratory for Research and Evaluation of Drug Metabolism, Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, 510515, China.

<sup>4</sup> Guangdong Provincial Key Laboratory of Shock and Microcirculation, Southern Medical University, Guangzhou, 510515, China.

<sup>5</sup> Bioland Laboratory (Guangzhou Regenerative Medicine and Health Guangdong Laboratory), Guangzhou, 510005, China

<sup>6</sup> State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau, China

<sup>7</sup> Department of Cardiology and Pneumology, University Medical Center of Göttingen, Georg-August-University, Göttingen, Germany

# Shunyi Li and Jianglian She contributed equally to this work.

\*Correspondence should be addressed to Dingli Xu, Lan Tang, Xuefang Zhou and Qingchun Zeng

32

33

## Contents

### 34 **Supplementary Figures and Tables**

35 Methods and Materials.

36 Figure S1. Structures of piericidin analogues PA, GPA, S14, S18 and S40.

37 Figure S2. MS, <sup>1</sup>H-, <sup>13</sup>C-NMR spectra of PA.

38 Figure S3. MS, <sup>1</sup>H-, <sup>13</sup>C-NMR spectra of GPA.

39 Figure S4. MS, <sup>1</sup>H-, <sup>13</sup>C-NMR spectra of S14.

40 Figure S5. MS, <sup>1</sup>H-, <sup>13</sup>C-NMR spectra of S18.

41 Figure S6. MS, <sup>1</sup>H-, <sup>13</sup>C-NMR spectra of S40.

42 Figure S7. Effect of GPA on the expression of IL-37 protein in HAVICs.

43 Figure S8. Docking results of some piericidin aglycones binding with IL-37 (6NCU).

44 Figure S9. Renal function in mice fed an adenine diet or after vitamin D injection.

45 Table S1. Demographic Characteristics of Enrolled Patients

46 Table S2. The primer sequences used for RT-qPCR.

47

48

49

50

51

52 **Methods and Materials.**

53

54 **1.Cell Viability Analysis.** HAVICs ( $3 \times 10^3$ ) were cultured in each well of a 96-well  
55 plate in M199 growth medium supplemented with 10% FBS for 24 hours. Then, the cells  
56 were starved in serum-free medium for 12 hours. Subsequently, the cells were treated  
57 with different final concentrations of S18 (0-4  $\mu$ M) for 48 hours. Cell viability was  
58 analyzed using CCK-8 assay kits (Glpbio, GK10005, USA). CCK8 solution was added to  
59 each well of the plate according to the manufacturer's instructions, and the plate was  
60 incubated in an incubator with 5% CO<sub>2</sub> at 37°C for 3 hours. The absorbance of the  
61 samples was determined spectrophotometrically at 450 nm using a microplate reader.

62 **2.Immunoblotting.** Immunoblotting was applied to analyze ICAM-1 (Santa Cruz, Sc-  
63 8439), IL-8 (Proteintech, 27095-1-AP), MCP-1 (Abclonal, A7277), IL-37 (Abcam,  
64 ab278499), phosphorylated NF- $\kappa$ B p65(Cell Signaling Technology, 3033), total p65 (Cell  
65 Signaling Technology, 8242) levels. Briefly, cells were lysed in lysis buffer (Solarbio,  
66 R0010) containing phosphatase and protease inhibitors (Solarbio, P6730, P1260) and  
67 quantified with a bicinchoninic acid protein assay. The protein samples were transferred  
68 onto PVDF membranes (EMD Millipore, Billerica, MA, USA). After blocking with 5%  
69 skim milk in TBST solution (Boster, AR0031) at room temperature for 1 hour, the  
70 blocked membranes were incubated overnight at 4°C with primary antibodies. After  
71 washing with TBST, the membranes were incubated with HRP-conjugated secondary  
72 antibodies specific to the primary antibodies for 1 hour at room temperature. GAPDH  
73 (Protechtein, 60004-1-Ig) and  $\beta$ -actin (Protechtein, 66009-1-Ig) was analyzed for  
74 normalizing protein loading. In the phosphorylation assay, total NF- $\kappa$ B were used for  
75 normalization. Finally, immunoreactive bands were detected with FDbio-Dura ECL Kit  
76 (Fdbio Science, FD8020) and GeneGnome imaging system (Syngene, Frederick, MD,  
77 USA). The images were analyzed with ImageJ software.

78 **3.ELISA.** Cell culture supernatants were obtained. The levels of IL-8 and MCP-1 were  
79 detected using ELISA kits (R&D, DY208, DY279) as described in the manufacturer's  
80 protocol.

81 **4.RNA Purification and Quantitative Real-time Polymerase Chain Reaction(qRT-  
82 PCR).** Total RNA was extracted from HAVICs using EZ-press RNA Purification Kit  
83 (EZBioscience, B004D) following the manufacturer's instructions. The cDNA for each

84 sample was reverse transcribed using the EVO M-MLV First Strand cDNA Synthesis Kit  
85 (Accurate Biotechnology(Hunan)Co.,Ltd, AG11706). PCR was performed using SYBR  
86 Green premix Pro Taq HS qPCR Kit (Accurate Biotechnology(Hunan)Co.,Ltd, AG11701)  
87 and LightCycler 480 (Roche Diagnostics, Basel, Switzerland). The following primers  
88 were used to amplify specific cDNA fragments: human ICAM-1, human IL-8, human  
89 MCP-1, GAPDH, and the sequences were listed in Table S2. The mean relative gene  
90 expression was calculated with the  $2^{-\Delta\Delta Ct}$  method after normalization of the cycle  
91 threshold (Ct) values to GAPDH gene expression.

92 **5. ROS and MMP Detection.** ROS levels were detected using DCFH-DA (Beyotime,  
93 S0033S) as described in the manufacturer's protocol. The MMP was determined using  
94 the JC-1 Kit and TMRE Kit (Beyotime, C2001S) following the manufacturer's  
95 instructions. For mitochondrial staining, cells were incubated in M199 medium  
96 containing 100 nmol/L MitoTracker Green (Beyotime, C1048) in dark at 37°C for 30  
97 minutes. Cell nuclei were stained with Hoechst 33342 (Beyotime, C1022) for 10 min.  
98 The images were acquired using a Leica TCS SP8 and were analyzed using ImageJ  
99 software.

100 **6. Histopathological and Immunofluorescence Staining.** After cell treatment,  
101 HAVICs were rinsed briefly with PBS, fixed in 4% paraformaldehyde for 15 minutes,  
102 and permeabilized with PBS containing 0.3% Triton X-100 for 10 minutes at room  
103 temperature. Nonspecific immunoreactions were blocked using 5% BSA in PBS for 1  
104 hour at room temperature. HAVICs were incubated overnight with primary antibodies  
105 against NF- $\kappa$ B p65 (Cell Signaling Technology, 8242). After secondary antibody  
106 (Proteintech, SA00013-2) incubation, the cell nuclei were stained with DAPI (Solarbio,  
107 C0060) for 15 minutes, and then confocal images were visualized using Leica TCS SP8.

108 A similar protocol was performed to stain the tissue sections. The mouse valves and  
109 human valves were deparaffinized with xylene and grades of ethanol, followed by antigen  
110 retrieval. After permeabilization and blocking with 5% BSA for 1 hour, the sections were  
111 incubated with primary antibodies against ALP (ABclonal, A1080), BMP2 (Abcam,  
112 ab214821). After washing with PBS, the sections were incubated with secondary  
113 antibodies conjugated to Alexa Fluor 552 (Proteintech, SA00009-1, SA00009-2). Cell

114 nuclei were stained with DAPI for 15 minutes, and images were acquired using a Leica  
115 TCS SP8.

116 **7.Von Kossa Staining.** Calcium deposition staining in mouse aortic valve was stained  
117 using Von Kossa Kit (Servicebio, G1042) according to the manufacturer's protocol.  
118 Calcium depositions in the mouse aortic valves were evaluated in vivo using ImageJ  
119 software.

120

121

122

123

124

125

126

127

128

129

130

131

132


133

134

135

136

137




138

139 **Figure S1** Structures of piericidin analogues PA, GPA, S14, S18 and S40

140


141



142

143


A) HR-MS (+) spectrum of PA.



144

145

B) <sup>1</sup>H NMR spectrum of PA (in CDCl<sub>3</sub>, 500 MHz).



146

147

C) <sup>13</sup>C NMR spectrum of PA (in CDCl<sub>3</sub>, 125 MHz).

148


**Figure S2.** MS, <sup>1</sup>H-, <sup>13</sup>C-NMR spectra of PA.

149



150


Display Report					
<b>Analysis Info</b>			Acquisition Date 10/25/2017 3:29:56 PM		
Analysis Name	D:\Data\amazon SLMS\data\201710\zhouxuefeng_ikl-11_61_01_338.d		Operator	bruker	
Method	338.m		Instrument	amazon SL	
Sample Name	zhouxuefeng_ikl-11				
Comment					
<b>Acquisition Parameter</b>					
Ion Source Type	ESI	Ion Polarity	Positive	Alternating Ion Polarity	on
Mass Range Mode	Enhanced Resolution	Scan Begin	100 m/z	Scan End	2000 m/z
Capillary Exit	140.0 V	n/a	n/a	Trap Drive	51.2
Accumulation Time	4955 $\mu$ s	Averages	5 Spectra	Auto MS/MS	off



151

152


A) HR-MS (+) spectrum of GPA.



153

154

B) <sup>1</sup>H NMR spectrum of GPA (in DMSO-d<sub>6</sub>, 700 MHz).



155


156

C) <sup>13</sup>C NMR spectrum of GPA (in DMSO-*d*<sub>6</sub>, 175 MHz).

157 **Figure S3.** MS, <sup>1</sup>H-, <sup>13</sup>C-NMR spectra of GPA.

158


159



160

161


A) ESI-MS (+) and ESI-MS (-) spectra of S14.



162

163

B) <sup>1</sup>H NMR spectrum of S14 (in DMSO-d<sub>6</sub>, 700 MHz).



C)  $^{13}\text{C}$  NMR spectrum of **S14** (in  $\text{DMSO-}d_6$ , 175 MHz).

**Figure S4.** MS,  $^1\text{H}$ -,  $^{13}\text{C}$ -NMR spectra of **S14**.

164

165

166


167

168

169

## Mass Spectrum SmartFormula Report

Analysis Info		Acquisition Date		1/13/2017 10:22:15 AM	
Analysis Name	D:\Data\MS\data\201612\zhouxuefeng_lxw-s18_neg_62_01_2956.d				
Method	LC ms2_Direct Infusion_neg_100-1000mz.m				
Sample Name	zhouxuefeng_lxw-s18_neg		Operator	SCSIO	
Comment			Instrument	maXis 255552.00029	
Acquisition Parameter					
Source Type	ESI	Ion Polarity	Negative	Set Nebulizer	0.4 Bar
Focus	Active	Set Capillary	3800 V	Set Dry Heater	180 °C
Scan Begin	100 m/z	Set End Plate Offset	0 V	Set Dry Gas	4.0 l/min
Scan End	2000 m/z	Set Charging Voltage	0 V	Set Divert Valve	Waste
		Set Corona	0 nA	Set APCI Heater	0 °C



Meas. m/z	#	Ion Formula	Score	m/z	err [ppm]	err [mDa]	mSigma	rdB	e <sup>-</sup> Conf	N-Rule
754.365969	1	C37H56NO15	100.00	754.365544	-0.6	-0.4	8.2	10.5	even	ok
790.345431	1	C37H57CINO15	100.00	790.342221	4.1	3.2	128.1	9.5	even	ok

zhouxuefeng\_lxw-s18\_neg\_62\_01\_2956.d  
Bruker Compass DataAnalysis 4.1

printed: 1/13/2017 2:26:24 PM


by: SCSIO

Page 1 of 1

170

171

### A) HRESIMS (-) spectrum of S18.




### B) <sup>1</sup>H NMR spectrum of S18 (in DMSO-d<sub>6</sub>, 700 MHz).

172

173

174



175

176


C)  $^{13}\text{C}$  NMR spectrum of **S18** (in  $\text{DMSO-}d_6$ , 175 MHz).

177

**Figure S5.** MS,  $^1\text{H}$ -,  $^{13}\text{C}$ -NMR spectra of **S18**.

178

179




180

likunlong\_LKL-23\_pos\_71\_01\_4461.d  
 Bruker Compass DataAnalysis 4.1  
 printed: 3/29/2018 9:28:53 AM  
 by: SCSIO  
 Page 1 of 1

181


A) HRESIMS (+) spectrum of S40.



182

183

B) <sup>1</sup>H NMR spectrum of S40 (in CD<sub>3</sub>OD, 700 MHz).



184



185

C)  $^{13}\text{C}$  NMR spectrum of S40 (in  $\text{CD}_3\text{OD}$ , 175 MHz).

186 **Figure S6.** MS,  $^1\text{H}$ -,  $^{13}\text{C}$ -NMR spectra of S40.

187






189  
 190 **Figure S7. Effect of GPA on expression of IL-37 protein in HAVICs.** (A) Human AVICs were  
 191 stimulated with 200 ng/ml LPS and then treated or not treated with GPA for 24 hours. Immunoblotting  
 192 revealed the expression of Expression in human AVICs. n=4.

193  
 194  
 195  
 196  
 197  
 198  
 199  
 200

201 **Figure S8. Docking results of some piericidin aglycones binding with IL-37 (6NCU).**




202  
203

204 **Figure S8** The binding affinity was identified by MST assay and the binding mode as well as sites of  
205 ligands were predicted by molecular docking analysis, indicating that S40 could perfectly combine with IL-  
206 37 protein but S14 and PA displayed weak binding ability. The detailed docking mode of (A) S40/IL-37,  
207 (B) S14/IL-37 and (C) PA/IL-37 with docking pock. (D) Affinity activity of S40/IL-37, S14/IL-37 and  
208 PA/IL-37 binding analyzed by MST assay, n = 3. (E) Docking scores of heparin, S18, GPA, S14, S40 and  
209 PA.

210

211

212 **Figure S9**



213

214

215 **Figure S9. Renal function in mice fed an adenine diet or after vitamin D injection.** The IL-37

216 overexpression mice were fed adenine diet for 21 days. (A) The levels of serum creatinine and BUN were

217 increased. But no difference was found between adenine group and S18 group. (B) The content of serum

218 creatinine and BUN also have high levels with no difference between Vit D group and S18 group. n=5, ns

219  $p > 0.05$ , # $p < 0.05$ .

220

221

222

223

224

225

226 **Table S1. Demographic Characteristic of Enrolled Patients**

	Non-CAVD patients (n=4)	CAVD patients (n=5)
Age (years)	56.0 ± 4.79	63.6 ± 6.04
Male, n (%)	2 (50%)	3 (60%)
BMI (Kg/m <sup>2</sup> )	27.7 ± 1.34	25.7 ± 1.79
Hypertension, n (%)	3 (75%)	3 (60%)
Dyslipidaemia, n (%)	1 (25%)	2 (40%)
Diabetes mellitus, n (%)	1 (25%)	1 (20%)
Smoking history, n (%)	1 (25%)	2 (40%)
β-blockers, n (%)	3 (75%)	1 (20%)
ACE inhibitors/ARB, n (%)	3 (75%)	4 (80%)
Statins, n (%)	2 (50%)	3 (60%)
LVEF (%)	57.4 ± 7.72	62.8 ± 2.73
AO (cm/s)	-	367.4 ± 30.31

227

228 Data are presented as mean ± SEM, n (%), or median (interquartile range). ACE, angiotensin-converting  
 229 enzyme; ARB, angiotensin receptor blocker; AO, aorta valve peak flow velocity; BMI, body mass index;  
 230 CAVD, calcific aortic valve disease; LVEF, left ventricle Ejection fraction;

231

232

233

234

235

236

237

238

239

240

241

242

243  
244  
245

**Table S2. The primer sequences used for RT-qPCR.**

Species	Gene name		Primer (5'- 3')
human	ICAM-1	F	TGACCGTGAATGTGCTCTCC
		R	TCCCTTTTTGGGCCTGTTGT
	IL-8	F	GGAGAAGTTTTTGAAGAGGGCTG
		R	ACAGACCCACACAATACATGAAG
	MCP-1	F	CAGCCAGATGCAATCAATGCC
		R	TGGAATCCTGAACCCACTTCT
	IL-37	F	TTCTTTGCATTAGCCTCATCCTT
		R	CGTGCTGATTCCTTTTGGGC
	GAPDH	F	GGCAAGGTCATCCCAGAGCT
		R	CCCAGGATGCCCTTTAGTGG

246  
247  
248  
249  
250